# Endometrial Cancer Aspirin has one of the stronger gynaecological evidence signals in **endometrial cancer**. The case is still built mainly on observational data. Even so, the pattern is unusually coherent. Prevention signals, obesity-linked subgroup effects, and supportive post-diagnosis data all point in the same direction. ### Overview Endometrial cancer is tightly linked to **obesity**, **oestrogen excess**, and **chronic inflammatory signalling**. That matters because aspirin directly intersects with this biology. It suppresses **COX-driven prostaglandin signalling**, lowers **TXA2** activity, and may weaken the inflammatory loop that helps drive endometrial proliferation and malignant change. [Read the meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC7210134/) Compared with ovarian cancer, this looks like the clearer aspirin page in gynaecological oncology. The signal is more consistent, the mechanism is more direct, and one retrospective study also suggests a survival benefit after diagnosis. [Read the gynaecological review](https://journals.sagepub.com/doi/10.1177/1745506520961710) ### Key human data #### Prevention and risk reduction The strongest endometrial-cancer pattern is not simple long duration. It is **frequency of aspirin use**. * **Meta-analysis of 18 studies:** Aspirin use was associated with lower endometrial-cancer risk in both case-control and cohort data. Reported effect sizes were **OR 0.88** in case-control studies and **RR 0.92** in cohort studies. [Read the meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC7210134/) * **Higher-frequency use:** Women using aspirin at least **twice weekly** showed a stronger signal, with an odds ratio of **0.63** in one synthesis. [Read the gynaecological review](https://journals.sagepub.com/doi/10.1177/1745506520961710) * **Australian National Endometrial Cancer Study:** Use of **two or more tablets per week** was associated with an odds ratio of **0.54**, which is close to a **50% relative risk reduction**. [Read the gynaecological review](https://journals.sagepub.com/doi/10.1177/1745506520961710) * **Overweight and obese women:** A 2024 QIMR Berghofer analysis reported about **15% lower risk** in overweight or obese women using aspirin or NSAIDs more than once weekly. [Read the QIMR summary](https://www.qimrb.edu.au/whats-on/news/aspirin-and-similar-drug-use-linked-to-lower-endometrial-cancer-risk-in-overweight-women) This obesity signal matters. Endometrial cancer is one of the clearest cancers where adipose inflammation, prostaglandins, and local oestrogen production reinforce each other. #### Survival after diagnosis Direct treatment-trial data is still missing. But one multicentre retrospective study reported that **low-dose aspirin use after diagnosis** was associated with better **5-year disease-free survival** and **overall survival**. [Read the report summary](https://mdedge.com/oncologypractice/article/107518/gynecologic-cancer/aspirin-may-improve-survival-endometrial-cancer) This should be treated as supportive, not definitive. Still, few non-colorectal aspirin pages have both a prevention signal and a post-diagnosis survival signal. ### Mechanistic relevance #### COX-2, PGE2, and oestrogen amplification This is the main biological reason the page matters. In obesity-linked endometrial cancer, excess adipose tissue raises local oestrogen production and inflammatory prostaglandins at the same time. **COX-2** drives **PGE2** production. **PGE2** can increase aromatase activity in adipose tissue. That increases local oestrogen production, which then further supports endometrial proliferation. [Read the meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC7210134/) Aspirin interrupts this loop upstream. It reduces prostaglandin production and may blunt the inflammatory-oestrogen feedback cycle that is especially active in obese patients. Low-dose aspirin has also been reported to reduce basal systemic **PGE2 biosynthesis** by about **55%** in healthy women. That gives this mechanism a direct pharmacodynamic anchor. [Read the meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC7210134/) #### PIK3CA relevance Endometrial cancer is also a plausible **PIK3CA-linked** aspirin setting. **PIK3CA** mutations occur in roughly **30% to 35%** of endometrial cancers. That is one of the highest rates among solid tumours. [Read the AACR pan-cancer analysis](https://aacrjournals.org/mct/article-pdf/19/12/2454/1863694/2454.pdf) That does **not** mean aspirin is validated here the way it now is in biomarker-selected colorectal cancer. It does mean the biology overlaps with the same mutation-defined logic that made the **ALASCCA** colorectal result so important. #### Platelet and TXA2 biology Platelet signalling may add a second layer of relevance. Aspirin irreversibly blocks platelet **COX-1** and sharply lowers **TXA2** generation. That matters because TXA2 can suppress immune surveillance during metastatic spread. For the broader mechanism, see [Aspirin and Thromboxane A2 (TXA2)](/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/anticancer-mechanisms/aspirin-and-thromboxane-a2-txa2.md). ### Clinical positioning | Setting | Evidence | Position | | ----------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------- | | **Prevention with frequent use** | Repeated observational signal, including stronger benefit at **two or more uses per week**. [Read the gynaecological review](https://journals.sagepub.com/doi/10.1177/1745506520961710) | Strongest endometrial signal | | **Overweight or obese women** | Lower risk appears more pronounced in obesity-linked settings. [Read the QIMR summary](https://www.qimrb.edu.au/whats-on/news/aspirin-and-similar-drug-use-linked-to-lower-endometrial-cancer-risk-in-overweight-women) | Best-supported subgroup | | **Post-diagnosis low-dose aspirin** | Retrospective survival signal only. [Read the report summary](https://mdedge.com/oncologypractice/article/107518/gynecologic-cancer/aspirin-may-improve-survival-endometrial-cancer) | Supportive, not practice-changing | | **PIK3CA-mutant disease** | Strong biological rationale. No dedicated endometrial trial. [Read the AACR pan-cancer analysis](https://aacrjournals.org/mct/article-pdf/19/12/2454/1863694/2454.pdf) | Plausible future biomarker subgroup | | **Infrequent long-term use** | Signal looks weaker than frequent use. [Read the meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC7210134/) | Not the best-supported pattern | ### Practical interpretation Endometrial cancer is one of the more biologically coherent aspirin pages outside colorectal cancer. The useful patient-level questions are: 1. Has the tumour had **genomic profiling**, especially for **PIK3CA**? 2. Was the cancer strongly linked to **obesity**, **metabolic syndrome**, or **chronic inflammatory pressure**? 3. Is the main discussion about **prevention**, **recurrence risk**, or **post-diagnosis adjunctive use**? 4. Given bleeding risk and GI history, is **low-dose aspirin** a reasonable discussion with the gynaecological oncology team? The main limit is still trial quality. Most evidence here is observational. But the overall picture is stronger than the old placeholder version suggested. ### References * 2020 meta-analysis of aspirin and endometrial-cancer risk — 18 studies, pooled prevention signal. [Read the meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC7210134/) * 2020 review of aspirin in gynaecological cancers — includes higher-frequency endometrial findings. [Read the review](https://journals.sagepub.com/doi/10.1177/1745506520961710) * QIMR Berghofer 2024 — lower endometrial-cancer risk in overweight and obese women using aspirin or NSAIDs. [Read the summary](https://www.qimrb.edu.au/whats-on/news/aspirin-and-similar-drug-use-linked-to-lower-endometrial-cancer-risk-in-overweight-women) * Multicentre retrospective report — low-dose aspirin and survival after endometrial-cancer diagnosis. [Read the report summary](https://mdedge.com/oncologypractice/article/107518/gynecologic-cancer/aspirin-may-improve-survival-endometrial-cancer) * Yang et al., *Nature* 2025 — platelet **TXA2**, immune escape, and metastasis. [Read the University of Cambridge summary](https://www.cam.ac.uk/research/news/scientists-discover-how-aspirin-could-prevent-some-cancers-from-spreading) * AACR pan-cancer analysis — **PIK3CA** mutation frequency context across tumour types. [Read the analysis](https://aacrjournals.org/mct/article-pdf/19/12/2454/1863694/2454.pdf)

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

{% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/endometrial-cancer.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.